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Abstract 
The article describes the application of a twin-screw granulationprocess to enhance the 
dissolution rate of the poorly water soluble drug, ibuprofen (IBU). A quality-by-design 
(QbD) approach was used to manufacture IBU loaded granules via hot-melt extrusion (HME) 
processing. For the purpose of the study,a design of experiment(DoE) was implemented to 
assess the effect of the formulation compositions and the processing parameters. This novel 
approach allowed the use of,polymer/inorganic excipients such as hydroxypropyl 
methylcellulose (HPMC) and magnesium aluminometasilicate (Neusilin®-MAS)with 
polyethylene glycol 2000 (PEG) as the binder without requiring a further drying step. IBU 
loaded batches wereprocessed using a twin screw extruderto investigate the effectof 
MAS/polymer ratio, PEG amount (binder) and liquid to solid (L/S) ratios on the 
dissolutionrates,mean particle size and the loss on drying (LoD) of the extruded granules. The 
DoE analysisshowed that the defined independent variables of the twin screw granulation 
process have a complex effect on the measured outcomes. The solid state analysis showed the 
existence of partially amorphousIBU state which had a significant effect on the dissolution 
enhancement in acidic media. Furthermore, the analysis obtained from the surface mapping 
by Raman showed the homogenous distribution of the IBU in the extruded granulation 
formulations. 
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1.0 Introduction 
In the recent years,increasing the solubility and thus the bioavailabilityof poorly water 
soluble drugs found in oral dosage forms has become a real challenge in pharmaceutical 
product manufacturing. This has been reflected by the exponential rise in the number 
ofpoorly water-solubledrugs in the pharmaceutical pipeline (Maniruzzaman et al., 2013a). 
Wet granulation has been adopted asa common process primarily used in the manufacture of 
pharmaceutical products such as oral solid dosage forms.Historically, the granulation 
processes has been optimised using conventional high shear and fluidised bed granulation 
which are suitable for batch manufacturing and are limited by the regulatory 
issues(Leuenberger, 2001; Lodaya et al., 2003). Currently twin-screw granulation (TSG) 
captures a growing interestdue to its emerging potential for continuous manufacturing. TSG 
is easy to scale up for product commerciallizationwith improved manufacturing efficiency 
such asreduced production costsand foot print (Cartwright et al., 2013; Keleb et al., 2002; 
Vervaet and Remon, 2005). Recently the Food and Drugs Admirations (FDA)agency 
supported the shift from batch mode production to continuous processes which is considered 
a fundamental step change in the pharmaceutical manufacturing and product development. 
Since, the implementation of TSG in mid eighty’s inthe production of paracetamolbased 
extruded granules, this technology has been adopted significantly to primarilyfocus on its 
pharmaceutical applications and theprocess technology(Keleb et al., 2004a,b, 2002; 
Kleinebudde and Lindner, 1993; Schmidt and Kleinebudde, 1998). A thorough comparison 
between twin screw granulation techniques and the traditional granulation methods such as 
high shear granulator (Keleb et al., 2004a; Schmidt and Kleinebudde, 1998) revealed that the 
twin-screw systems could be used as an alternative continuous manufacturing platform. In a 
continuous TSG, a higher product yield is achieved by removing the die block at the end of 
the extruder barrel and thus avoidance of over-compression of the granules is occurred.  
Several studies on TSG havesignificantly explored the influence of process parameters 
and formulation variables on thecritical quality attributes of granulated materials (Dhenge et 
al., 2013, 2012; El Hagrasy et al., 2013; El Hagrasy and Litster, 2013; Lee et al., 2012; 
Thompson and Sun, 2010; Tu et al., 2013). RecentlyYu et al., (2014), investigated the 
granulation behaviour of three formulations containing increasing amounts of hydrophobic 
components using a twin screw granulator. The authors studied the process conditions 
including powder feed rate, liquid to solid ratio, granulation liquid composition and screw 
configuration as key parameters to implement a design of experiment (DoE) space. These 
studies have improved the understanding of the effects of input material properties and 
processing conditions when optimising a TSG.  
Up to date, various studies have been reported on the wet granulations for the formation 
of the unit dose whereby in-process intermediates of appropriate size, flowability and 
compressibility are produced prior to down streaming processes such as tabletting. However, 
the majority of those reported studies have either focused on the compressibility or the 
process optimisation, but none or very little have reported on the actual effect of this 
innovative technology on the dissolution rates of poorly water soluble drugs (e.g. ibuprofen). 
Moreover, the use of inorganic excipients such as magnesium aluminometasilicate (MAS) 
(Gupta et al., 2002) as drug carries in TSG for increased dissolution rates of poorly water-
soluble drugs can be an attractive approach providing a new insight into translational 
pharmaceutical research and product development. 
MAS is an amorphous magnesium aluminometasilicate with a high specific surface 
area (300 m2/g) (Gupta et al., 2003) presenting exceptional excipients properties such as high 
flowability, high surface area, porous, thermal and mechanical stability for improved API 
delivery and the quality of pharmaceutical dosage forms. Ibuprofen is a BCS class II drug 
with high permeability and low solubility which has been previously processed via 
conventional HME for the development of polymeric solid dispersion (Maniruzzaman et al., 
2012; 2013a, b). The aim of this article is toexploit the application of TSG to enhance 
ibuprofen dissolution rates combined with a design of experiment (DoE). The MAS/Polymer 
ratios, PEG amount as granulating liquid and liquid to solid ratio (L/S) were considered as 
variables whereas the drug release rate, mean particle size (MPS) and loss on drying (LoD) 
was measuredas response. 
2. MATERIALS AND METHOD 
2.1 Materials 
Ibuprofen(IBU) was purchased from Tokio Chemical Industries (Belgium) and 
magnesium aluminometasilicate (MAS-Neusilin® US2) was kindly donated by Fuji 
Chemical Industries Co., Ltd. (Japan). Hydroxy propyl methyl cellulose based polymer 
Pharmacoat 603 (HPMC) was kindly donated by ShinEtsu, Japan. Polyethylyneglycole 2000 
(PEG) was purchased from Sigma Aldrich (Gillingham, UK). All solvents used were of 
analytical grade and used as received. 
 
2.2 Twin screw granulation and DOE analysis 
The granulation experiments were conducted using the twin screw granulator 
(EuroLab 16, ThermoFisher, Germany) with a screw diameter (D) of 16 mm and barrel 
length of 40D (L/D ratio 40). The screw configuration used had three kneding zones with 
same numbers of kneading blocks each. The first kneading zone was configured at 30o, 40o 
and 60o angle while the second kneading zone was configured at 60o followed by a third 
kneading zone just before the die end at 90o angles. During the process, the dry blends of the 
physical mixtures of the drug, polymer/ inorganic carrier and granulating aid PEG (8-12% 
w/w ratio) were dispensed into the granulator via a volumetric feeder (Brabender, Germany) 
at 1 kg/h feed rate. The DoE experiment designs are shown in Table 1. A peristaltic pump 
enabling the sufficient flow of water as liquid binder was employed to drive the flow of the 
granulation liquidsat a varying flow rate of 4.16-6.67 ml/min for 25-40% (w/w ratio) water 
(Fig. 1). The pumps were interfaced with a flow meter to achieve the precise control of the 
mass flow rate. All extruded granules were further micronized by using a cutter mill (Retsch, 
Germany) with 250 µm mesh. 
Extruded granules with different compositions were obtained by incorporating a 
threefactorresponse surface fraction factorial design (DoE) inrandomized order by using 
Fusion One software (DoEFusion OneTM, USA). Three centrepoint experiments 
wereperformed as well, resulting in 23+3=11 experiments. Drug loading was kept constant 
while MAS/Polymer ratios, granulating liquid concentrations and L/S ratio were considered 
as variables whereas drug release rate, MPS and LoDwas measuredas dependant 
variables/response. 
2.3 Particle size analysis 
The particle size distributions of the granules were determined using a Mastersizer 
2000 laser diffraction instrument (Malvern Instruments, UK) with a dry powder sample 
dispersion accessory (Scirocco 2000) and pressure at 2 bar and a vibration feed rate of 50%. 
Samples were run in triplicate. Mastersizer 2000 software was used for data evaluation.The 
specific surface area (SSA) of all granules was also measured simultaneously during the 
particle size analysis by the Mastersizer.The d(50) reported is the geometric median particle 
size; the d(10) and d(90) are the particle diameters at 10 and 90% of the cumulative volume 
distribution, respectively. The span of the volume distribution, a measure of the width of the 
distribution relative to the median diameter, was calculatedusing the following equation (Eq. 
1). 
 
2.4 Scanning electron microscopy (SEM) 
SEM was used to study the surface morphology of the hot-melt extrudates. The 
samples were mounted on an aluminium stage using adhesive carbon tape and placed in a low 
humidity chamber prior to analysis. Samples were coated with gold, and microscopy was 
performed using a Cambridge Instruments (S630, UK), SEM operating at an accelerating 
voltage of 5 kV. 
2.5 X-ray powder diffraction (XRPD) 
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XRPD was used to determine the solid state of pure active substances, physical 
mixtures and extruded materials using a Bruker D8 Advance (Germany) in theta-theta mode. 
For the study purposes a Cu anode at 40kV and 40mA, parallel beam Goebel mirror, 0.2 mm 
exit slit, LynxEye Position Sensitive Detector with 3° opening (LynxIris at 6.5 mm) and 
sample rotation at 15 rpm were used. Each sample was scanned from 2 to 40° 2ɵ with a step 
size of 0.02° 2Ɵ and a counting time of 0.1 seconds per step;  176 channels active on the PSD 
making a total counting time of 35.2 seconds per step 
2.6 Differential scanning calorimetry (DSC) study 
A Mettler-Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter 
(DSC) was used to carry out DSC runs of pure actives, physical mixtures and extrudates. 
Approximately2-5 mg of sample was placed in sealed aluminium pans with pierced lids.  The 
samples were heated at 10°C/min from 0°C to 220°C under dry nitrogen atmosphere and 
reheated at the same heating rate. 
In addition, modulated temperature differential scanning calorimetry (MTDSC) 
studies were performed from 25oC to 200oC with an underlying heating rate of 2oC/min. The 
pulse height was adjusted to 2oC with a temperature pulse width of 15-30 s. 
2.7 Dynamic vapour sorption (DVS) analysis 
Vapour sorption of spray-dried powders was investigated by means of an automated 
gravimetric vapour sorption analyser, DVS Advantage-1 (Surface Measurements Systems 
Ltd, UK). The DVS Advantage-1 uses a Cahn D200 recording ultramicrobalance with a mass 
resolution of ±0.1 μg; the vapour partial pressure around the sample is controlled by mixing 
saturated and dry carrier gas streams (N2) using electronic mass flow controllers (Amaro et 
al., 2015). Samples were equilibrated at 0% RH until dry and the reference mass was 
recorded. The samples were exposed to the following relative humidity (% RH) profile: 0 to 
90% in 10% steps and the reverse for desorption at 25.0±0.1°C. At each stage, the sample 
mass was allowed to reach equilibrium, defined as dm/dt=0.002 mg/min over 10 min, before 
the RH was changed. The amount of water uptake for each RH stage was expressed as a % of 
the dry sample mass (m0). 
2.8 Raman mapping to study the drug distribution 
Room temperature Raman spectra of the “pure” formulation components were 
obtained using a Jobin/YvonLabRam 320 instrument equipped with an Olympus microscope 
(Horiba, Japan). The spectrometer is equipped with a 1800 grooves/mm holographic grating, 
a holographic notch filter, a Peltier-cooled CCD (MPP1 chip) for detection, and an Olympus 
BX40 microscope. An Ar+ ion laser (λ = 532.8 nm) was used. Raman spectra of solid-state 
samples were collected at room temperature on a microscope slide using a microscope 
objective of 50× magnification to focus the laser beam. A backscattering (180° between 
excitation and collection) geometry was used in all experiments. Each spectral scan was 
collected for 5 s using 4 accumulations. The Raman instrument was calibrated using the v1 
line of silicon at 520.7 cm−1. Centering of the silicon line was checked by using the 
frequencies of the principal lines of a neon lamp. 
Raman mapping(Lee et al., 2011; Islam et al., 2015)was performed using a 
Jobin/YvonLabRam 320 instrument equipped with an Olympus microscope (Horiba, Japan) 
by means of Ar+ ion laser (λ = 532.8 nm) and 1800 l/nm grating on 3 different particles for 
each formulation (Supp. Fig. 1). The experimental conditions were: 100 nm slit width, a 50× 
Microsoft objective and 0.4 s acquisition time. Each spectrum was the mean of the two. The 
sample profiling was performed at step increments of 3 μm in the X–Y direction covering the 
biggest possible surface of the part.  
In order to investigate the distribution of IBU in the formulations univariate analysis 
has been applied by using its characteristic peak at 1609cm-1.The data analysis were principal 
component analysis (PCA) as a precursor method to identify the number of component. 
Subsequently, multivariate curve resolution – alternate least square (MCR - ALS) was used to 
decompose the hyperspectral data matrix. Prior to analysis, the spectra were baseline by using 
the automatic weighted lest square and normalised to unit area to avoid deviation among the 
Raman spectra.  
 
2.9 In vitro dissolution study 
In vitro drug release studies were carried out in 900 ml of both 0.1 M HCl (pH 1.2) 
and 0.2 M dihydrogen-sodium-orthophosphate (pH adjusted with NaOH to 6.8) for 2 hr using 
a Varian 705 DS dissolution paddle apparatus (Varian Inc. North Carolina, US) at 100 rpm. 
Dissolution bath and vessels were then equilibrated to 37 ± 0.5°C. At predetermined time 
intervals, samples were withdrawn for HPLC assay. All dissolution studies were performed in 
triplicate. 
2.10 HPLC analysis  
 The release of IBU was determined by using HPLC, Agilent Technologies system 
1200 series. A HYCHROME S50DS2-4889 (5 µm x 150 mm x 4mm) column was used for 
the HPLC analysis of IBU. The wavelength was set at 214 nm. The mobile phase consisted of 
acetonitrile/water/phosphoric acid (65/35/0.2 v/v) and the flow rate was maintained at 1.5 
ml/min and the retention time was 2-3 min(Gryckze et al., 2011; US Pharmacopeia, 2015). 
Calibration curve was prepared with concentrations varying from 10 µg /ml to 50 µg/ml and 
20 µl injection volumes. 
 
3. RESULTS AND DISCUSSION 
3.1 DOE analysis of extrusion granulation 
The main objective of this study was not only to manufacture extruded granules 
processed via continuous twin-screw granulation but also to investigate the effect of various 
processing parameters/ conditions to identify and define the design space. For the purpose of 
the study a DoE was implanted to investigate the effect of process variables (independent) 
such as the MAS/Polymer ratio (A), the binder amount (B) and the liquid/solid (C) ratio on 
the granulation process.  The drug dissolution rate, the mean particle size (MPS) and the loss 
of drying (LoD) were selected as the dependent variables. The relationship and the effect 
ofthe three inputs on all of the targeted response were investigated further. The drug 
concentration in all formulations was kept constant at 40% (w/w ratios) by keeping the final 
dosage of IBU (200 mg) in account. The processing conditions such as screw speed, screw 
configurations and feed rate were also kept steady in order to reduce experiments and the 
number of processing parameters. 
The experimental plan with the discrete values of the independent variables and the 
measured valuesof the dependent variables are depicted in Supp. Table 1a. The regression 
analysis of the DoE revealed interesting results for the extrusion granulation process. As it 
can be seen from Supp. Table 1b there is a quadratic effect of the MAS/Polymer factor (p = 
0.01) and no significant effect of the other main process variables on the drug release rates 
(p>0.05). Interestingly, a two – way interaction of the binder amount and the L/S ratio has a 
significant effect on the drug release. The most complex effect appeared on the LOD where 
both binder amount (linear) and L/S (quadratic) were found to present a significant effect (p < 
0.05). Interestingly, two – way interactions of the A/B and B/C appeared to havea significant 
effect on the LOD. These two – way interactions indicate a synergetic effect for each of the 
variable pairs. Finally, the obtained granules particle size is affected significantly (Supp. 
Table 1c) by the MAS/Polymer ratio and the two – way interaction between the 
MAS/Polymer ratio and the binder amount. The DoE analysis shows that the defined 
independent variables of the extrusion granulation process have a complex effect on the 
measured outcomes. Thus, further process optimization will require the implementation of an 
advanced DoE such as a response surface design.  The response surface maps for each 
dependent variable are depicted in Fig. 2. 
3.2 Particle morphology 
SEM was used to examine the surface morphology of the bulk IBU and the extruded 
granules. As can be seen in Fig. 3(a), bulkIBU appeared as needle type crystalsfalling in the 
micro range. In contrast, for all IBU extruded granules, no drug crystals were observed on the 
granulated surface suggesting excellent mixing during the high shear granulation (torque ~3.6 
– 5.2 Nm, engine load ~0.05-0.10 KW) inside the extruder barrel. This may result in a 
possible drug adsorption into the porous MAS network in room temperature for the 
granulated formulations (Fig. 3b-d). Further information provided in supplementary data 
(Supp. Fig. 2). It can also be seen that all IBU loaded granules appeared as agglomerates of 
microstuctured particles. This formation of such extruded granules with drug adsorption and 
reduced granular particle size during extrusion can be of great interest for the development of 
oral dosage forms with enhanced dissolution rates of poorly water-solubledrugs.  
Particle size volume distributions for all extruded granules were either monomodal or 
dimodal withlow spanvalues (1.5 to 13.3) (Supp. Fig. 3). The geometric medianparticle size 
(d50) for all IBU extruded granules was in therange of 100–305μmand the SSA was 0.04-
0.92 m2/g. Thed(50) values ofall extruded granules are summarized in Table 1 (and 
Supp.Table 1c)and affectedmainly by the MAS/Polymer amounts and the two way interaction 
with the binder amounts. Furthermore the response surface maps (Fig. 2) shows that granule 
particle sizes (100 - 110m) are obtained for MAS/Polymer ratios close to 1 while binder 
amounts vary from 5-8%.  For any other MAS/Polymer ratio the granule particle size 
increases up to 305m. The DOE regression analysis also revealed that the L/S ratio did not 
present any effect on the granule size which was in a good agreement with previous studies 
(Dhenge et al. 2012).  
The LoD values of the extruded granules are not affected by the MAS/Polymer ratios 
but are heavily depend on the binder amounts and the L/S ratios.  The contour map (Supp. 
Fig. 4) shows that low LoDs can be achieved for low L/S ratios (0.25 – 0.30) and high binder 
concentrations (8 – 12%).  The manufacturing of granules with low LoD is very important for 
the development of solid dosage forms such as tablets in order to avoid powder sticking on 
the tablet press punches or capping and lamination of the compressed tablets in a later stage.  
A novel aspect of the implemented granulation process is the fact that excellent 
granules with optimised particle size distribution and low LoD values can be obtained 
without using an additional drying step. The granule drying is a critical step in continuous 
granulations. This was attributed to the unique combination of inorganic and polymer 
excipients 
3.3 X-ray powder diffraction (XRPD) 
X–ray analysis of bulk substances and the IBU/MAS/HPMC/PEG granules, was 
conducted in order to examine the crystalline state of the drug.  As can be seen in Fig. 4,  the 
diffractogram of pure IBU presented distinct intensity peaks due to its crystalline structure at 
6.03o, 12.09o, 16.48o, 17.55o, 18.75o, 20.02o, 22.13o, 24.47o, 24.99o 2θ degrees while PEG 
exhibited two characteristic intensity peaks at 19.01o and 23.49o2θ degrees. In contrast both 
MAS and HPMC appeared as completely amorphous (no crystalline intensity peaks). The 
extruded granules of all IBU formulationsshowed identical peaks due to the presence of 
crystalline IBU in the formulations at relatively lower intensities suggesting that the 
amorphicity of the highly crystalline drug has been increased during the high shear 
granulation processing even at high 40% drug loading (%, w/w).  
3.4 DSC analysis 
DSC was used to determine the solid state of the drug in the extruded granules. Supp. 
Fig. 5a represents the thermal transitions of pure IBU, PEG and MAS. The bulk IBU showed 
an endothermic thermal transition at 77.79oC (H = 92.99 j/g), which corresponds to its 
melting peak while PEG exhibited an endothermic sharp melting peak at 52.82oC (H = 
133.39oC). In contrast, the bulk HPMC did not show any transitions due to it amorphous 
nature. Similarly, theMASdid not present any endothermic thermal event suggesting that the 
inorganic MAS is amorphous with relatively higher glass tranistions. The DSC analysis (Fig. 
5 and Supp. Fig. 5b) of the physical blends of all formulations showed an endothermic 
thermal transition at about 53-54oC corresponding to the melting of crystalline PEG followed 
by another thermal event at about 77oC corresponding to the melting of IBU present in the 
formulations. Similarly, the DSC thermograms of extruded granules showed the melting 
peaks of IBU at relatively lower temperature attributed to the amorphcity increase of the IBU 
in the extruded granules as complemented by XRD analysis above. This could also be for the 
partial solubilisation of the drugs in low melting point PEG and entrapment in the porous 
network of inorganic MAS. The thermal transition due to the melting of IBU in the extruded 
formulations were visible at 61.79-67.29oC just after the melting transitions of the crystalline 
PEG.   
3.5 DVS analysis 
The effect of moisture on thesolid-state stability of the drug in different granules 
prepared via the continuous twin screw granulation processing was investigated by DVS. It 
was expected thatthe inclusion of hydrophilic HPMC and PEG along with MAS would lead 
to an increase in the wateruptake capacity of the extruded granules. The presence of MAS in 
the formulations will ease the water uptake as it works as an excellent proton donor and 
receptor due to the presence of sinalols in its structure. Fig. 6shows the water vapour sorption 
isotherms for three different extruded granules.F2 took up approximately 3.73% by mass at 
60% RH (25oC and 40oC temperature) followed by a significant increase of up to 
13.20%bymassof moisture at 100% RH.The desorption isothermshows steady water loss, 
resulting in a reversible process. Similar vapour sorption isotherms were seen for F10 where 
about 9.88% by massat 100% RH was increased in the absorption segment at both 25oC and 
40oC suggesting that the vapour sorption was not dependant on the temperature but the RH 
%.In contrary, F11 showed an interesting event in both the sorption and the desorption 
segment. Unlike at 40oC, it took up a very little mass of moisture at 25oC with no further 
water loss or gainin the desorption isotherm represented by a steady line at 25oC, resulting in 
an openhysteresis(Tewes et al., 2010). These events are believed to occur as a results of 
partial amorphous IBU collapsing into its crystalline stableform, as crystalline phases are less 
hydrophilic than amorphousones. Similar studies were reported elsewhere(Amaro et al., 
2015). Excessive amount of PEG (12% w/w) present in the formulation F11 may have played 
a vital role for this event while F2 and F10 both have lesser amount in the formulations. It 
can also be seen from DVS analysis that up to 30% of water as a granulating liquid could 
prove to be optimum for developing stable granules for dissolution enhancement purpose via 
twin-screw granulations.  
3.6 Confocal Raman mapping 
The Raman spectra of the pure compoundsare represented in Supp. Fig. 6. As it can 
be observed, IBU has a characteristic peak at 1609 cm-1 which has been used to investigate 
the distribution of the drug in the formulation by means of univariate analysis. Fig. 7(a-c) 
demonstrates the distribution of IBU in all the particle area. However, in F1 IBU is not 
evenly dispersed as there is an area (bottom right corner) with higher concentration (Fig. 7a). 
Additionally, in order to investigate the homogeneity of the formulation multivariate data 
analysis has been used. Specifically, PCA was applied as a precursor to MCR to reduce the 
number of variables and identify the number of components. In general, the decision of when 
to stop extracting principal components basically depends on when there is only very little 
"random" variability left. The nature of this decision is arbitrary; however, various guidelines 
have been developed. One of the most common approach used in Raman mapping is Kaiser 
Criterion where the PCs that are retained have eigenvalues more than F1. Based on this 
criterion, it is clear that in F2 and F6 the system can be described by using only one 
component which contains peaks from all the compounds indicating the homogeneity of the 
samples where F1 will use four components to decompose the hyperspectral data matrix. It is 
worth noting that the graphs of eigenvalues have already suggested that the F2 and F6 are 
more homogenous than F1.  
In terms of F1, the hyperspectral data matrix was decomposed in four components. 
Fig. 6b represents some characteristic bands of the compounds that appear in the first four 
components after MCR decomposition. Hence, as it can be seen components 1 and 2 contain 
peaks attributed to IBU and PEG only, whereas characteristic peaks of MAS and HPMC 
appeared in the 4th components at 587cm-1 and 290cm-1respectively. Other bands are possible 
to appear but they were not able to distinguish as they are overlapped with the strong IBU 
peak.  Finally, Fig. 7a also illustrates the areas that correspond to the components 1, 2 and 4 
where it can be seen that HPMC has not covered the whole area. This has also been 
confirmed by applying Classical Least Square method (CLS) (data are not represented). It is 
worth mentioning that the main reason of this non-homogenous distribution is the appearance 
of amorphous and crystalline drug. In crystalline IBU the peaks in the region 780 – 835 cm-1 
are more acute as in the case of component 1, whereas the amorphous drug gives broader 
peak in this region similar to component 4 (Hédoux et al., 2011). Consequently, HPMC may 
inhibit drug’s crystallisation as these two compounds co-exist in the same face.  
In terms of F2 and F6, the data matrix was decomposed in three components (Fig. 7b-
c). As it can be seen, these components are similar and contain peaks related to all the 
compounds confirming the homogeneity of these formulations. Moreover, the IBU in these 
formulations are in partially amorphous state leading to a more uniform formulation.    
3.7In vitro dissolution studies 
The main aim of the study was to manufacture granulated formulations to impact on 
the dissolution profiles of hydrophobic drug IBU.In Fig. 8, it can be seen that the 
manufactured granules with high drug loading 40% (w/w ratios)showed significant increase 
in the dissolution rate of IBUvarying from 60-85% within 120 min complying with the USP 
monograph (USPharmacopeia, 2015).Additional results are provided in Supp. Fig. 7a. As 
mentioned previously regressionanalysis showed significant effect of the MAS/Polymer ratio 
and a two –way interaction of the B/C factors on the release patterns.  As shown in the 
contour map of Supp. Fig. 7b, high IBU release rates can be obtained for equalMAS/Polymer 
amounts (1:1 ratio), high binder amounts (> 8%) and low L/S ratios (<0.3). Thus F2, F10 and 
F11 showed the high IBU release rates with the latter being the optimal formulation for the 
extrusion granulation processing. This particular formulation outperformed the rest 
compositions due to the appropriate MAS/Polymer ratio (1:1) and the synergetic effect of the 
high binder amount (12%) and low L/S ratio (0.25).  As a result F11 presented the high 
dissolution rates, narrow particle size distribution and low LoD value.   
4.0 Conclusions 
A twin screw continuous granulationprocess was used to manufacture IBU loaded 
fast-release granulesby investigating the effect of MAS/Polymer ratio, PEG concentration, 
and L/S ratio on the dependant variables such as release, mean particle size and LoD. By 
implementing a DoE approach,it was revealed that the defined independent variables of the 
twin screw granulation process have a complex effect on the measured outcomes.The solid 
state analysis showed the existence of the IBU in its partially amorphous forms which may 
have significant effect on the dissolution enhancement. Furthermore, the analysis obtained 
from the surface mapping by Raman showed the homogenous distribution of the IBU 
granules in the granulated formulations. An important aspect of the granulation process was 
the absence of a further drying step and the optimization of granules with the optimum 
specifications. This promising paradigm ofQbD approach can be used in the future for 
process optimizationand better understanding of the developed pharmaceuticalformulations 
via twin-screw granulation. 
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TABLES 
Table 1:Experimental design of continuous granulation formulationswith MAS/Polymer 
ration, binder amount (%) and L/S ratio as independent variables and Release (%), particle 
size D(0, 5), and LoD (%) as dependent variables. 
 
 
Run 
No. 
Process independent variables Process dependent variables 
MAS/Polymer 
ratio 
Binder  
(%) 
L/S ratio 
 
Release (%) 
T2h 
D(50) 
(µm) 
LoD 
(%) 
F1 2.0 8.0 0.25 61.89 150 1.82 
F2 1.0 8.0 0.30 75.61 100 1.88 
F3 0.33 8.0 0.30 48.76 152 2.14 
F4 2.0 5.0 0.40 47.26 305 2.37 
F5 2.0 12.0 0.30 50.01 170 2.22 
F6 1.0 8.0 0.40 61.35 106 1.82 
F7 0.33 12.0 0.40 37.61 245 2.84 
F8 0.33 5.0 0.25 42.19 124 4.05 
F9 1.0 5.0 0.30 50.79 109 3.29 
F10 1.0 8.0 0.30 84.02 136 2.15 
F11 1.0 12.0 0.25 86.50 124 1.26 
 
 
 
 
 
 
 
 
 
 
Figures caption list 
 
Fig
. 1 
Instrumentation set up for twin-screw granulation comprising of a Eurolab 16 extruder and the 
granulating liquid feeding pump. 
Fig
. 2 
Response surface for IBU release and mean particle size in the DoE design space. 
Fig
. 3 
SEM images of (a) bulk IBU, (b) F1, (c) F2 and (d) F6 extruded granules. 
Fig
. 4 
XRPD diffractograms of pure substances and various extruded granules. 
Fig
. 5 
DSC thermograms of extruded granules. 
Fig
. 6 
DVS analysis of water sorption and desorption of F1, F2 and F6 granules. 
Fig
. 7 
(a), (b) and (c) eigenvalues results (top left), MCR –also components where * represent peaks 
of IBU, $ represents peaks of PEG, # peak of HPMC and & peak of MAS (top right), 
concentration map of IBU as generated using univariate analysis (bottom left) and 
concentration map of comp. 1 (black), comp 2 (red) and comp 4 (green, bottom right) for F1, 
F2 and F6, respectively. 
Fig
. 8 
In vitro dissolution studies of IBU from the extruded granules in F2, F10 and F11 (n=3, 37oC, 
100 rpm). 
 
  
 
 
 
  
 
 
 
 
  
 
  
 
  
 
 
 
